Compare HRMY & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRMY | NWN |
|---|---|---|
| Founded | 2017 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 2018 |
| Metric | HRMY | NWN |
|---|---|---|
| Price | $37.03 | $48.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $44.11 | ★ $54.33 |
| AVG Volume (30 Days) | ★ 854.1K | 293.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | 7.97 | ★ 36.45 |
| EPS | 0.55 | ★ 2.33 |
| Revenue | $868,453,000.00 | ★ $1,289,363,000.00 |
| Revenue This Year | $19.75 | $11.37 |
| Revenue Next Year | $12.88 | $4.46 |
| P/E Ratio | $67.75 | ★ $21.34 |
| Revenue Growth | ★ 21.51 | 11.83 |
| 52 Week Low | $25.52 | $39.29 |
| 52 Week High | $40.87 | $55.99 |
| Indicator | HRMY | NWN |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 45.46 |
| Support Level | $35.05 | $48.32 |
| Resistance Level | $39.12 | $50.17 |
| Average True Range (ATR) | 1.04 | 1.09 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 93.53 | 18.71 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.